Developing a vaccine to protect against different types of Salmonella infections
Target Antigen Identification to Generate a Cross-serovar Salmonella Vaccine
This study is working on a new vaccine to help protect people from different types of Salmonella infections, which can be quite serious, by looking at how the immune system reacts in mice to find the best ways to make the vaccine effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11123758 on NIH RePORTER |
What this research studies
This research focuses on creating a vaccine that can protect against various serovars of Salmonella, which are responsible for serious infections. The team will use a new mouse model to study how the immune system responds to both typhoidal and non-typhoidal Salmonella infections. By comparing these responses, researchers aim to identify key protective antigens that can be targeted in vaccine development. This approach is crucial as current vaccines only address typhoidal Salmonella, leaving a gap for other dangerous strains.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for Salmonella infections, particularly those in regions where these infections are prevalent.
Not a fit: Patients who are not at risk for Salmonella infections or those who have already been vaccinated against the specific serovars being targeted may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces the incidence of systemic Salmonella infections, potentially saving many lives.
How similar studies have performed: While there have been successful vaccine developments for typhoidal Salmonella, this approach to create a cross-serovar vaccine is relatively novel and has not been extensively tested.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Mcsorley, Stephen J — University of California at Davis
- Study coordinator: Mcsorley, Stephen J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.